Trump's Generic Drug Tariffs Could Hit India, the 'Pharmacy of the World'

A new tariff plan proposed by former US President Donald Trump targeting generic drugs could have profound implications for India, a nation often referred to as the "pharmacy of the world." The plan, which outlines potential tariff rates of 0%, 100%, and 200%, has sparked considerable concern within India's pharmaceutical sector.

India plays a critical role in global healthcare by supplying generic medicines to numerous countries. In the United States alone, Indian generic drugs account for approximately 40% of the market share by volume. This significant presence underscores India's importance in ensuring affordable access to essential medications worldwide.

The proposed tariffs introduce a layer of uncertainty for India's export-oriented pharmaceutical industry. The varying rates suggest a potentially complex and unpredictable trade environment, which could disrupt established supply chains and impact the competitiveness of Indian generic drug manufacturers. The long-term consequences for both the US healthcare system and India's economy remain a subject of intense scrutiny.